These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38405668)

  • 1. Editorial: Repurposing β-blockers for non-cardiovascular diseases.
    Shahid A; Wang J; Andresen BT; Chen SRW; Huang Y
    Front Pharmacol; 2024; 15():1372317. PubMed ID: 38405668
    [No Abstract]   [Full Text] [Related]  

  • 2. Repurposing of drugs approved for cardiovascular diseases: Opportunity or mirage?
    Gelosa P; Castiglioni L; Camera M; Sironi L
    Biochem Pharmacol; 2020 Jul; 177():113895. PubMed ID: 32145263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Anti-ulcerogenic Effect of the Beta-adrenergic Blockers on Diabetic Foot Ulcers: Recent Advances and Future Prospectives.
    Singh P; Sharma S; Sharma PK; Alam A
    Curr Diabetes Rev; 2024; 20(8):23-37. PubMed ID: 37867269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing beta-blockers for combinatory cancer treatment: effects on conventional and immune therapies.
    Massalee R; Cao X
    Front Pharmacol; 2023; 14():1325050. PubMed ID: 38264530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery.
    Mostafaie K; Bedenis R; Harrington D
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD006342. PubMed ID: 25879091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Present trends and controversies in the use of beta-blockers in cardiovascular diseases].
    Spoladore R; Fragasso G; Montanaro C; Maranta F; Torlasco C; Gerosa S; Margonato A
    Recenti Prog Med; 2010 Nov; 101(11):429-41. PubMed ID: 21197763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Update on beta blockers in 2020].
    Bejan-Angoulvant T; Angoulvant D
    Rev Med Interne; 2020 Nov; 41(11):741-747. PubMed ID: 32532560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three Generations of β-blockers: History, Class Differences and Clinical Applicability.
    do Vale GT; Ceron CS; Gonzaga NA; Simplicio JA; Padovan JC
    Curr Hypertens Rev; 2019; 15(1):22-31. PubMed ID: 30227820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of calcium channel blockers in diabetic renal transplant patients: preliminary observations on protection from sepsis.
    Weinrauch LA; D'Elia JA; Gleason RE; Shaffer D; Monaco AP
    Clin Nephrol; 1995 Sep; 44(3):185-92. PubMed ID: 8556835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating Carvedilol's Repurposing for the Treatment of Non-Small Cell Lung Cancer via Aldehyde Dehydrogenase Activity Modulation in the Presence of β-Adrenergic Agonists.
    Ikhmais BA; Hammad AM; Abusara OH; Hamadneh L; Abumansour H; Abdallah QM; Ibrahim AIM; Elsalem L; Awad M; Alshehada R
    Curr Issues Mol Biol; 2023 Sep; 45(10):7996-8012. PubMed ID: 37886948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Beta-adrenergic receptor blockers in clinical practice].
    Czuriga I; Edes I
    Orv Hetil; 2004 Sep; 145(38):1951-60. PubMed ID: 15535106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bench-to-bedside review: Beta-adrenergic modulation in sepsis.
    de Montmollin E; Aboab J; Mansart A; Annane D
    Crit Care; 2009; 13(5):230. PubMed ID: 19863760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
    Embaby A; van Merendonk L; Steeghs N; Beijnen J; Huitema A
    Front Oncol; 2022; 12():940582. PubMed ID: 36185303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing of approved cardiovascular drugs.
    Ishida J; Konishi M; Ebner N; Springer J
    J Transl Med; 2016 Sep; 14():269. PubMed ID: 27646033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well.
    Frishman WH
    Prog Cardiovasc Dis; 2016; 59(3):247-252. PubMed ID: 27984052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in Ca2+ entry blockers revealed by effects on adenosine- and adrenergic- receptors and cyclic AMP levels of [2-3H]adenine-prelabeled vesicles prepared from guinea pig brain.
    Psychoyos S; Bax M; Atkins C
    Biochem Pharmacol; 1986 May; 35(10):1639-46. PubMed ID: 3011009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardio-selective versus non-selective β-blockers for cardiovascular events and mortality in long-term dialysis patients: A systematic review and meta-analysis.
    Tao S; Huang J; Xiao J; Ke G; Fu P
    PLoS One; 2022; 17(12):e0279171. PubMed ID: 36534654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure.
    Zhang X; Shen C; Zhai S; Liu Y; Yue WW; Han L
    Exp Ther Med; 2016 Oct; 12(4):2489-2496. PubMed ID: 27703506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blockers: Historical Perspective and Mechanisms of Action.
    Oliver E; Mayor F; D'Ocon P
    Rev Esp Cardiol (Engl Ed); 2019 Oct; 72(10):853-862. PubMed ID: 31178382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
    Mehvar R; Brocks DR
    J Pharm Pharm Sci; 2001; 4(2):185-200. PubMed ID: 11466176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.